Skip to main content
Trials logoLink to Trials
. 2022 Feb 15;23:150. doi: 10.1186/s13063-022-06080-8

Correction to: Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection: A structured summary of a study protocol for a randomized controlled trial

Javed Akram 1, Shehnoor Azhar 2,, Muhammad Shahzad 3, Waqas Latif 4, Khalid Saeed Khan 5
PMCID: PMC8845337  PMID: 35168638

Correction to: Trials 21, 702 (2020)

https://doi.org/10.1186/s13063-020-04616-4

Following the publication of the original article [1], we were notified of the below corrections:

1- In the Intervention and Comparator section, Phosphate is erroneously mentioned.

2- In the Participants section, “Participants of any gender or age group having tested positive” should read “Participants of either gender above 18 years of age”.

Reference

  • 1.Akram J, et al. Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of hydroxychloroquine, oseltamivir and azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21:702. doi: 10.1186/s13063-020-04616-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Trials are provided here courtesy of BMC

RESOURCES